Aspirin forudsiger potentialet for at forebygge leverkræft

Del dette indlæg

The researchers found that taking two or more standard doses (325 mg) of pills per week reduced the risk of liver cancer by 49%. Compared with people who do not often use aspirin or do not use aspirin, the frequent use of aspirin causes a significantly lower risk of liver cancer. With the extension of aspirin dose and duration of use, the risk of liver cancer gradually decreased. However, it should be noted that this study does not prove that aspirin can reduce the risk caused by the liver, but there is a correlation.

In this study, the researchers analyzed long-term data for more than 45 800 women and 87 500 men in the United States. The researchers report that the protective effect of aspirin increases over time. In patients taking aspirin for 5 years or more, the risk of liver cancer was reduced by 59%. Studies have shown that regular use of non-steroidal anti-inflammatory drugs such as acetaminophen (Tylenol) or febuprofen (Motrin, Advil) is not related to reducing the risk of liver cancer. The results were published in “JAMA Oncology”.

However, routine use of aspirin increases the risk of bleeding, and the next step should be to study its effect on patients with confirmed liver disease. Senior study author Dr. Andrew Chan noted that “aspirin has been recommended for use by some American adults to prevent heart disease and colorectal cancer.”

https://www.health24.com/Medical/Liver-Health/Liver-cancer/does-aspirin-help-prevent-liver-cancer-20181007

Abonner på vores nyhedsbrev

Få opdateringer og gå aldrig glip af en blog fra Cancerfax

Mere at udforske

Menneskebaseret CAR T-celleterapi: Gennembrud og udfordringer
BIL T-cellebehandling

Menneskebaseret CAR T-celleterapi: Gennembrud og udfordringer

Menneskebaseret CAR T-celleterapi revolutionerer kræftbehandling ved genetisk at modificere en patients egne immunceller til at målrette og ødelægge kræftceller. Ved at udnytte kraften i kroppens immunsystem tilbyder disse terapier potente og personlige behandlinger med potentiale for langvarig remission ved forskellige typer kræft.

Forståelse af cytokinfrigivelsessyndrom: årsager, symptomer og behandling
BIL T-cellebehandling

Forståelse af cytokinfrigivelsessyndrom: årsager, symptomer og behandling

Cytokine Release Syndrome (CRS) er en immunsystemreaktion, der ofte udløses af visse behandlinger som immunterapi eller CAR-T-celleterapi. Det involverer en overdreven frigivelse af cytokiner, der forårsager symptomer lige fra feber og træthed til potentielt livstruende komplikationer som organskader. Ledelse kræver omhyggelig overvågning og interventionsstrategier.

Brug for hjælp? Vores team er klar til at hjælpe dig.

Vi ønsker en hurtig bedring af din kære og nær en.

Start chat
Vi er online! Chat med os!
Scan koden
Hej,

Velkommen til CancerFax!

CancerFax er en banebrydende platform dedikeret til at forbinde individer, der står over for kræft i avanceret stadie, med banebrydende celleterapier som CAR T-Cell-terapi, TIL-terapi og kliniske forsøg verden over.

Fortæl os, hvad vi kan gøre for dig.

1) Kræftbehandling i udlandet?
2) CAR T-Cell terapi
3) Kræftvaccine
4) Online videokonsultation
5) Protonterapi